Peptilogics Founder and CEO, Jonathan Steckbeck, explained that PLG0206’s membrane-active mechanism enables it to destroy both active and dormant biofilm bacteria overcoming a key limitation of traditional antibiotics.
Jonathan Steckbeck
Advertisement
Articles by Jonathan Steckbeck
Peptilogics Founder and CEO, Jonathan Steckbeck noted that advances in peptide design and safety have positioned the field to address drug-resistant pathogens more effectively.
Peptilogics Founder, CEO, Jonathan Steckbeck, explained that PLG0206 stands apart from current treatments, while the company’s discovery platform transforms drug development from an iterative search process into a data-driven design model.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Bob Mauch: Strengthening the Chain
2
MJH Life Sciences Acquires BPD Healthcare, Expands Reach Among Health Systems and Innovators
3
Novo Nordisk Announces Major Shake Ups to Board
4
The Long-Term Outlook for MFN Pricing: Far-Reaching Issues and Considerations
5
